Abstract 129P
Background
In some Spanish regions, NGS is now publicly funded for certain tumor types with approved targeted therapies (e.g. NSCLC) or molecular diagnosis (e.g. sarcomas) as standard of care (SOC). Outside those indications, patients (pts) do not have access to NGS, limiting treatment (tx) opportunities. The Catalan Institute of Oncology (ICO) network of public cancer centers has implemented a centralized NGS prescreening program through institutional grants outside SOC indications in order to broaden tx options.
Methods
Retrospective cohort analysis of refractory solid tumors pts referred to the multicentric ICO Phase 1 Unit who underwent prescreening with the NGS panel TrueSightOncology500. We assessed the percentage of pts treated based on identified alterations, overall response rate (ORR) by RECIST1.1 and clinical benefit rate (CBR) [complete/partial response (PR) or stable disease for >4 months]. Progression-free and overall survival (PFS, OS) were also evaluated.
Results
From MAR22 to MAR24, 249 pts were included at 3 ICO centers: 54% female; most frequent tumors being colorectal (18.1%), urothelial (8%), endometrial (7.6%), ovarian (6.4%) and high-grade gliomas (6.4%); median prior lines of tx was 2 (0-7). 226 pts (95%) had some molecular alteration and 22 pts (10%) received tx accordingly within clinical trials or as compassionate use. Main targeted findings were HER2 amp, MSI, KRAS mut G12C, high TMB (>10 mut/Mb) and BRCA mut, among others (Table). From 14 evaluable pts, 1 achieved PR. CBR was 36% (5/14). Median PFS and OS were 2.9 (0.7-8.1) and 5.85 (1.4-16.6) months, respectively. Table: 129P
Target alteration | Frequency | % | Treatment |
HER2 amp | 4 | 18.2 % | paclitaxel-trastuzumab (2 pts) |
trastuzumab-lapatinib (1 pt) | |||
AXL inh + chemotherapy + trastuzumab (1 pt) | |||
MSI | 4 | 18.2 % | Anti-PD1 (2 pts) |
ATR inh (1 pt) | |||
Oncolytic virus + anti-PD1 (1 pt) | |||
KRAS mut G12C | 3 | 13.6 % | KRAS G12C inh (1 pt |
KRAS G12C inh + panitumumab (1 pt) | |||
KRAS G12C inh + PARP inh (1 pt) | |||
RAS/RAF WT | 3 | 13.6 % | SHP2 inh (3 pts) |
TMB | 2 | 9.1 % | Anti-PD1 (2 pts) |
BRCA mut | 2 | 9.1 % | Anti-PD1 + PARP inh (1 pt) |
PARP inh (1 pt) | |||
ALK fusion | 1 | 4.5 % | ALK inh (1 pt) |
ARID1A mut | 1 | 4.5 % | EZH2/EZH1 dual inh (1 pt) |
KRAS other mut | 1 | 4.5 % | MEK inh (1 pt) |
MET mut | 1 | 4.5 % | MET inh (1 pt) |
Conclusions
In our experience, a coordinated multicentric NGS prescreening program outside publicly funded SOC indications is feasible and useful, allowing access to additional tx in 10% of cases. Better selection of pts and wider availability of clinical trials will presumably increase clinical benefit in the next few years.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Catalan Institute of Oncology.
Disclosure
P. Sàbat Viltró: Other, Personal, Other, Training: Lilly; Other, Personal, Other, Congress registration: Gilead. J.J. Soto Castillo: Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Pfizer, Eisai, MSD, Seagen. M. Calvo: Financial Interests, Personal, Advisory Board: Roche, Eisai; Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca; Financial Interests, Personal, Other, Safety Phase I trial: Nerviano. M. Oliva Bernal: Financial Interests, Personal, Invited Speaker: Merck, MSD, BMS, MSD; Financial Interests, Personal, Advisory Board: Merck, MSD; Financial Interests, Personal, Invited Speaker, Teaching activities: MSD, Merck; Financial Interests, Personal, Other, IDMC: Transgene; Financial Interests, Personal and Institutional, Funding: Roche; Financial Interests, Institutional, Invited Speaker: ALX Oncology, MSD, ISA Therapeutics BV, Roche, Ayala Therapeutics, AbbVie, Bayer, Boehringer Ingelheim, Merck, Debiopharm, Seagen, Gilead, Beigene, Nykode; Financial Interests, Institutional, Funding: GSK; Non-Financial Interests, Institutional, Product Samples: Roche. J.C. Ruffinelli Rodriguez: Financial Interests, Personal, Invited Speaker: Amgen; Other, Personal, Other, Travel and Accommodation: MSD, Merck, Advanced Accelerator Applications, Esteve. R. Villanueva Vazquez: Financial Interests, Personal, Advisory Board: Seattle Genetics; Financial Interests, Personal, Other, Congress attendance registration: Pfizer, Novartis, Gilead, AstraZeneca, Daiichi Sankyo/AstraZeneca. C. Fina Planas: Financial Interests, Personal, Invited Speaker: BMS, Ipsen; Non-Financial Interests, Personal, Principal Investigator: Janssen. C. Hierro: Financial Interests, Personal, Invited Speaker: MSD, Lilly, AstraZeneca; Financial Interests, Personal, Research Grant, Principal Investigator of Merck Research Grant in Personalized Medicine 2020: Merck; Non-Financial Interests, Personal, Principal Investigator, Clinical Trial: BMS, Jazz Therapeutics, ALX Oncology, AstraZeneca, MSD; Other, Personal, Other, Travel fees: BMS, Amgen, Roche, Merck. M. Gil Martín: Financial Interests, Personal, Invited Speaker: MSD, GSK, Clovis; Financial Interests, Personal, Advisory Board: AstraZeneca. J. Martin-Liberal: Financial Interests, Personal, Invited Speaker: Astellas, Bristol Myers Squibb, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sanofi; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Novartis, Pierre Fabre, Roche, Sanofi, Highlight Therapeutics; Financial Interests, Personal, Other, Travel grant: Bristol Myers Squibb, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Ipsen, Merck. All other authors have declared no conflicts of interest.
Resources from the same session
104P - Comprehensive analysis of clinical characteristics and germline status among colorectal cancer patients in a tertiary care center in Thailand
Presenter: NUTDANAI ROILA
Session: Cocktail & Poster Display session
Resources:
Abstract
105P - Subsequent treatments after progression on cyclin-dependent kinase 4/6 inhibitors: A multicentric real-world data study
Presenter: Ana Rita Freitas
Session: Cocktail & Poster Display session
Resources:
Abstract
106P - Toxicity profile antibody-drug conjugates (ADCs) in metastatic breast cancer patients: A systematic review and meta-analysis based on studies’ design
Presenter: Silvia Belloni
Session: Cocktail & Poster Display session
Resources:
Abstract
107P - Receptor change on residual disease following neoadjuvant therapies for locally advanced breast cancer fails to impact oncological and survival outcomes
Presenter: Rionagh Lynch
Session: Cocktail & Poster Display session
Resources:
Abstract
114P - Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild type metastatic colorectal cancer in the CAPRI 2-GOIM trial
Presenter: Davide Ciardiello
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - Impact of tissue factor on clinical and biological characteristics in patients with advanced pancreatic cancer
Presenter: Taro Shibuki
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Multiomic profiling based on <italic>Akkermansia muciniphila</italic> in advanced non-small cell lung cancer
Presenter: Lorenzo Belluomini
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Transforming public patient omic data into precision oncology targets: A comprehensive pan-cancer approach
Presenter: Eléonore Fox
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Whole transcriptome sequencing of lung tissue to combine disease classification and identification of actionable targets
Presenter: Alejandro Pallares Robles
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - Genetic profiling of breast cancer in a developing country: Towards the establishment of oncogenetics in Cameroon
Presenter: Kenn Chi Ndi
Session: Cocktail & Poster Display session
Resources:
Abstract